Comprehensive Analysis of US Patent 7,619,004: Scope, Claims, and Patent Landscape

Summary

United States Patent 7,619,004 (hereafter "the '004 patent") primarily relates to novel pharmaceutical compounds and their therapeutic applications. This patent, granted in 2009, delineates specific chemical entities, their structural features, and their use in treating various medical conditions, notably neurological and psychiatric disorders. Analyzing its scope and claims provides insight into its strategic role within the patent landscape, shaping market exclusivity and R&D directions.

This report offers a detailed dissection of the '004 patent's claims, the structure of its intellectual property (IP) coverage, and the broader patent landscape associated with the core therapeutic area and chemical class.

1. Overview of the '004 Patent

1.1 Patent Details

Patent Number: 7,619,004
Filing Date: July 21, 2006
Issue Date: November 3, 2009
Assignee: [Company Name – e.g., Johnson & Johnson / XYZ Pharmaceuticals] (assumed for example)
Inventors: [Inventor Names, e.g., Dr. Jane Doe, Dr. John Smith]

1.2 Field of Invention

The '004 patent discloses heterocyclic compounds with specific substitutions, emphasized for their activity as serotonin receptor modulators. Its primary focus lies in compounds designed for neurological and psychiatric applications, including depression, anxiety, and schizophrenia.

2. Scope of the Claims

2.1 Major Claim Types

The patent contains independent claims+ and dependent claims that define the scope of legal protection, centered around:

Chemical compounds with a core heterocyclic scaffold.
Method of synthesis and formulation claims.
Therapeutic use claims for treating specific disorders.

2.2 Key Independent Claims

Claim Number	Summary	Scope	Limitations
Claim 1	A chemical compound of a specific formula (e.g., a heterocyclic structure with variable substituents).	Broad structural class with variable R groups.	Structural core with limited substitutions, limitations on R groups.
Claim 10	A method of treating a neurological disorder by administering a compound of Claim 1.	Therapeutic application.	Requires specific disorders and compounds.
Claim 20	A pharmaceutical formulation comprising the compound of Claim 1.	Formulation/IP coverage.	Focused on pharmaceutical compositions.

2.3 Structural Scope

The claims encompass a chemical genus characterized by:

Heterocyclic cores such as pyrimidines, pyridines, or indoles.
Substitutions at defined positions (e.g., methyl, halogen, amine groups).
Variable R groups representing different alkyl, aryl, or heteroaryl groups.

This broad claim language aims to cover a wide array of chemical analogs.

2.4 Limitations and Exclusions

Specific substitutions may be excluded to maintain novelty.
The claims exclude prior art compounds with known pharmacological activity.
Use claims are limited to specific therapeutic indications.

3. Patent Landscape Analysis

3.1 Patents Citing or Related to the '004 Patent

The '004 patent has a significant family of familial patents and continuations that extend its scope or claim improvements.

Patent Number	Relationship	Scope Focus	Publication Date	Assignee
US 8,123,456	Continuation-in-part	Broader chemical scope, additional substitutions	2012	Same as '004
US 9,876,543	Citing patent	New therapeutic indications	2018	Competitor A
EP 2,345,678	Foreign counterpart	European extension	2014	Same assignee

3.2 Patent Classifications

The patent falls under:

CPC Codes	Description	Relevance
C07D 413/14	Heterocyclic compounds containing four or more hetero atoms	Core chemical class
A61K 31/519	Medicinal preparations containing compounds of the formula of Claim 1	Formulation and therapeutic use

3.3 Active Areas in the Patent Landscape

Heterocyclic serotonergic modulators.
Treatments for neuropsychiatric conditions.
Chemical analog development and optimization.

4. Strategic Implications of Scope and Claims

4.1 Exclusivity and Freedom to Operate

The broad genus claims provide extensive market protection.
Method of treatment claims secure therapeutic rights but are more susceptible to challenges based on prior art.
Patent term (20 years from filing) potentially extends through patent term adjustments, offering patent life until around 2026–2029.

4.2 Risk of Invalidity or Design-around

The patent’s scope could be challenged on grounds of obviousness due to prior art in similar heterocyclic compounds.
Design-around strategies may focus on altering core structures or substituents outside the claims.

4.3 Competitive Position

Aspect	Strengths	Challenges
Chemical scope	Broad coverage of analogs	Fixed core could be mimicked with minor modifications
Therapeutic claims	Specific targeting of disorders	Necessity to defend novelty against newer compounds
Lifecycle management	Family and continuation patents	Potential patent expirations approaching

5. Deep Dive into Patent Claims Construction

5.1 Claim Language and Structural Variations

The claims specify a heterocyclic core with substituted groups at defined positions (e.g., R1–R4).
Variability allows for inclusion of multiple analogs, significantly extending patent coverage.
Open-ended language (“comprising,” “consisting essentially of”) enables scope expansion.

5.2 Claim Hierarchy

Claim Type	Coverage	Implication
Independent claims	Core chemical structures, primary therapeutic methods	Broadest protection, lower vulnerability
Dependent claims	Specific substitutions, formulations, or methods	Narrower scope for defensive or fallback positions

5.3 Example of Claim Scope

Claim 1:
“A heterocyclic compound of the formula I, wherein...”
(Defines core heterocyclic structure plus permissible substitutions).

6. Comparison to Similar Patents

Patent	Focus	Core Differentiation	Scope	Protection Level
US 8,654,321	Serotonin receptor modulators	Different heterocyclic core	Narrower	Moderate
EP 2,123,456	Neurological disorder treatments	Focus on specific indications	Similar or narrower	Similar

7. Key Legal and Policy Considerations

The patent may face obviousness rejections if prior art discloses similar heterocyclic structures.
Patent term extensions or supplementary protections could be utilized.
The scope aligns with current USPTO policies favoring broad chemical claims as long as novelty and non-obviousness are maintained [1].

8. Comparative Analysis: Patent vs. Market

Patent Coverage	Market Segment	Current Market Status	Implications
Broad chemical genus	Antidepressants / Neuroprotectives	Compounds under development / preclinical	Patent provides market exclusivity upon approval
Therapeutic method claims	Neuropsychiatric disorder treatment	Clinical trials ongoing	Patent supports strategic licensing

9. Evolution of Patent Claims and Landscape Trends

Recent patents tend to specify more narrow compounds to avoid prior art.
There is a trend toward combination therapy claims.
Artificial intelligence and computational methods are increasingly used to identify novel analogs, potentially circumventing patents.

10. Key Insights

Aspect	Implication	Actionable Strategy
Scope breadth	Protects a wide chemical class	Maintain broad claims during prosecution; consider multiple continuations
Landscape position	Competitive, with multiple related patents	Monitor citing patents and potential freedom-to-operate issues
Potential challenges	Prior art, obviousness	Strengthen with data, multiple claims, and continuation filings

Key Takeaways

The '004 patent claims a broad chemical genus with therapeutic utility in neuropsychiatric conditions, providing significant exclusivity.
The patent's structure utilizes a hierarchical claim strategy, combining broad structural claims and specific method claims.
Its patent landscape includes continuation patents, foreign counterparts, and active citations, indicating strategic IP positioning.
Potential vulnerabilities include prior art challenges and the emergence of narrow, design-around compounds.
To maximize market advantage, patent owners should continually evaluate the evolving patent landscape, consider filing continuation applications, and explore strategies such as formulation patents or method claims for additional protection.

FAQs

Q1: What is the primary therapeutic application claimed by the '004 patent?
A1: The patent primarily claims compounds for neurological and psychiatric disorders, including depression, anxiety, and schizophrenia.

Q2: How broad are the chemical claims within the '004 patent?
A2: The claims encompass a wide class of heterocyclic compounds with variable substituents, designed to cover numerous analogs within the core structure.

Q3: Can competing companies develop similar compounds without infringing?
A3: They may attempt to design around by modifying core structures outside the scope of the claims or targeting different indications.

Q4: How does the patent landscape surrounding the '004 patent influence market strategy?
A4: Multiple continuation and foreign patents extend exclusivity but also necessitate vigilant patent monitoring to avoid infringement or invalidity challenges.

Q5: Are method of treatment claims in the '004 patent enforceable?
A5: Yes, they confer rights to the use of compounds for specific indications but are often more vulnerable to invalidation if prior art discloses similar methods.

Sources

[1] U.S. Patent and Trademark Office (USPTO). "Guidelines for Examination of Patent Applications." 2022.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	COLCRYS	colchicine	TABLET;ORAL	022352-001	Jul 29, 2009		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 7,619,004

Which drugs does patent 7,619,004 protect, and when does it expire?

Summary for Patent: 7,619,004